Evaluation of 4 New Simplified Antiretroviral Treatments in Naive HIV-1 Infected Patients in Africa (ANRS 12115 DAYANA)
Merck Sharp & Dohme Corp.
Hopital de Fann, Dakar

      The goal of this trial is to demonstrate that new treatments are as effective as a reference
      triple-agent regimen in driving plasma viral load below the detection limit early during
      treatment (16 weeks). These simplified treatments involve fewer tablets and intakes,
      fixed-dose combinations, and also radically new strategies such as boosted protease inhibitor
      and tenofovir.
    
Drug